Novartis wins FDA approval for a form of chronic hives
Novartis' Rhapsido (remibrutinib) received FDA approval for treating symptomatic dermographism, a form of chronic hives. The approval follows a Phase III study showing 29.3% of patients had complete hives disappearance at Week 12, compared to 14% on placebo. Novartis shares rose 2.4% in Zurich and are up nearly 10% year-to-date, according to the company.
How this was made
The 30-second read
Why it matters
The approval opens a new revenue stream and validates the clinical approach, likely supporting a share price rally.
Market read
Regulatory win for a major pharma firm with immediate share price impact and sector‑wide implications.
What to watch
Reimbursement negotiations and competition from other antihistamine therapies could temper revenue growth.
Background
Novartis announced the first FDA approval for a drug specifically targeting symptomatic dermographism, expanding its BTK inhibitor portfolio.
Ticker impact
FDA approved Novartis' Rhapsido (remibrutinib) for symptomatic dermographism, a new indication in the U.S.
upside pressure as the market prices in the new indication and potential revenue uplift
The approval adds a first‑in‑class therapy for chronic hives, and the stock already jumped 2.4% on the news.
Market effects
Strengthens the biotech/dermatology segment and may boost peer BTK inhibitor developers.
Positive for European pharma stocks, especially those with U.S. regulatory pipelines.
Adds to the pipeline of FDA‑approved allergy treatments, a niche but growing market.
Counterpoint
If the market has already priced the approval, further upside may be limited.
Key entities
- companyNovartis
Swiss multinational pharmaceutical company.
- productRhapsido (remibrutinib)
BTK inhibitor approved for chronic hives.
